Lexaria Bioscience -

NASDAQ:LEXX

Home
About
Technology
Licensing Opportunities
Investors

Scientific Advisory Board

Lexaria Bioscience → Scientific Advisory Board

Member

Professor Philip Ainslie, Ph.D.

Member

Dr. Karen Aust, Ph.D.

Member and Chief Medical Advisor

Dr. Michael Gibson M.S., M.D.

Chairman

John Docherty

Lexaria Bioscience Corp. (NASDAQ:LEXX) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.

250.765.6424
[email protected]

Canadian Operations
#100-740 McCurdy Road
Kelowna, BC, V1X2P7

US Operations
210 Shamrock Industrial Blvd., Suite C
Tyrone, GA 30290

General Disclaimer:
No statement in this web site has been evaluated by the Food and Drug Administration (FDA). Furthermore, none of the statements in this web site should be construed as dispensing medical advice or making claims regarding the cure of diseases…

Read More

Copyright © 2024 Lexaria Bioscience. All rights reserved.